Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus acidophilus LA-10A
- Development stage
- Unknown
- Lead developer
- Thankcome Biotechnology
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Possibly Vaginal (for Some L. Acidophilus Strains)[4]
01
Overview
Lactobacillus acidophilus LA-10A is a specific strain of the species Lactobacillus acidophilus, a Gram-positive, rod-shaped, non-sporulating, anaerobic bacterium commonly found in the human gastrointestinal tract and oral cavity. L. acidophilus strains are widely used as probiotics due to their ability to survive acidic environments and confer health benefits by modulating gut microbiota, inhibiting pathogenic bacteria (such as Staphylococcus aureus and Clostridium perfringens), supporting digestion, and enhancing immune function[1][4]. The mechanism of action involves competitive exclusion of pathogens through adhesion to epithelial cells via S-layer proteins, production of lactic acid that lowers intestinal pH unfavorably for pathogens, and modulation of host immune responses[1][4]. Strain-specific effects may include support for antibiotic-associated diarrhea prevention or adjunctive therapy in gastrointestinal disorders; however, clinical evidence is often strain-dependent.
- Other names
- 嗜酸乳杆菌LA-10A
Beyond the preview
Go deeper on lactobacillus acidophilus LA-10A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus acidophilus LA-10A.